ObjectiveHealth Expands into New Therapeutic Areas, Adding Dermatology, Urology and Oncology to their Research Portfolio
Expansion will allow partnered specialists to participate in research in their communities
NASHVILLE, TN – November 3, 2022 – ObjectiveHealth, an integrated research provider and embedded technology platform company, announced today they are expanding into additional therapeutic areas which will open new research options to more than 14.4M patients within the communities they serve. Leveraging their proprietary technology solutions, the company will now be conducting clinical trials in dermatology, urology and oncology, in addition to gastroenterology, across their partnered research sites throughout the country.
Their dermatologic disease focus will include acne, atopic dermatitis, rosacea and psoriasis, which collectively impacts 84.5M people in the U.S. Similarly, their urology research will focus on population intensive disorders such as benign prostatic hypertrophy, kidney stone disease, urinary tract infections and overactive bladder. Research focus in these new specialties will also include interventional cancer trials and predictive biomarkers in precision medicine diagnostics.
“Expanding into new research therapeutic areas brings science to the point-of-care,” said Colleen Hoke, co-founder and chief executive officer of ObjectiveHealth. “Utilizing our established history of innovation and quality in clinical research, we have a tremendous opportunity to advance health outcomes.”
The company will utilize their proprietary screening technology, ObjectiveScreen, to find at-risk patients and deliver qualified research candidates that accelerates study timelines and decreases patient morbidity rates.
“With the support from our new partners, we are excited to provide access to advanced diagnostics and new therapy options for at-risk patients,” said Don Lazas, MD, co-founder and chief medical officer of ObjectiveHealth. “Providing patients with the option to participate in clinical research is critical to the overall health statuses of the communities we serve.”
This news comes one year after the company announced their name change to ObjectiveHealth, a strategic move that positioned the company to expand their clinical research capabilities across more healthcare research areas. Prior to this change, ObjectiveHealth had a primary scientific focus on prevalent gastrointestinal diseases, such as fatty liver disease, metabolic syndrome and next generation diagnostics.
ObjectiveHealth is a leading integrated research provider partnering with physicians and healthcare organizations to establish advanced infrastructure for research programs. The company takes an innovative approach to research that aims to improve patient outcomes at the point-of-care. Utilizing proprietary technology, processes, and trained on-site personnel, ObjectiveHealth delivers significant advances in the conduct of clinical research, benefiting clients and partners while providing broader care options for patients. With 29 partnered programs across 16 states and over 600 providers, ObjectiveHealth is poised for continued growth due to the realized value of their healthcare solutions for all stakeholders. To learn more, visit: www.objective.health.